Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease

Jaidyn Muhandiramge; Vivian Lee; Monica Tran; Lannie Ho

doi:10.1111/imj.16156

Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease

Intern Med J. 2023 Jul;53(7):1273-1276. doi: 10.1111/imj.16156. Epub 2023 Jun 29.

Authors

Jaidyn Muhandiramge^{1

2}, Vivian Lee², Monica Tran², Lannie Ho²

Affiliations

¹ School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
² Austin Health, Melbourne, Victoria, Australia.

PMID: 37384573
DOI: 10.1111/imj.16156

Abstract

Coadministration of ferric carboxymaltose and denosumab may cause hypocalcaemia and hypophosphataemia; however, this interaction is not well-described in the literature and has typically been described in patients with chronic kidney disease (CKD). We present a case of this interaction in a patient without preexisting CKD. We suggest the use of alternative iron preparations and an interval of at least 4 weeks between administrations.

Keywords: denosumab; ferric carboxymaltose; hypocalcaemia; hypophosphataemia; osteoporosis.

Publication types

Case Reports

MeSH terms

Anemia, Iron-Deficiency* / drug therapy
Denosumab / adverse effects
Humans
Hypocalcemia* / chemically induced
Hypocalcemia* / drug therapy
Hypophosphatemia* / chemically induced
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

ferric carboxymaltose
Denosumab